MY208153A - Solid dispersion and preparation method therefor - Google Patents

Solid dispersion and preparation method therefor

Info

Publication number
MY208153A
MY208153A MYPI2021007073A MYPI2021007073A MY208153A MY 208153 A MY208153 A MY 208153A MY PI2021007073 A MYPI2021007073 A MY PI2021007073A MY PI2021007073 A MYPI2021007073 A MY PI2021007073A MY 208153 A MY208153 A MY 208153A
Authority
MY
Malaysia
Prior art keywords
solid dispersion
preparation
method therefor
difluorophenoxy
ynyl
Prior art date
Application number
MYPI2021007073A
Inventor
Xianqiang Zhou
Zhenxing Du
Jie Wang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MY208153A publication Critical patent/MY208153A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Colloid Chemistry (AREA)

Abstract

Solid dispersion and a preparation method therefor. In a specific embodiment, the solid dispersion contains an active ingredient (R)-4-amino-1-(1-(but-2-ynyl)pyrrolidin- 3-yl) )-3-(4-(2,6-difluorophenoxy)phenyl) 1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7- one or a salt thereof, and a carrier material, and the pH value is adjusted; employing a method that adds an appropriate amount of acid 10 effectively inhibits an emulsification phenomenon in a reverse solvent process, thereby obtaining solid dispersion having a moderate particle size and uniform content.
MYPI2021007073A 2019-05-31 2020-05-29 Solid dispersion and preparation method therefor MY208153A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910468254 2019-05-31
PCT/CN2020/093206 WO2020239065A1 (en) 2019-05-31 2020-05-29 Solid dispersion and preparation method therefor

Publications (1)

Publication Number Publication Date
MY208153A true MY208153A (en) 2025-04-18

Family

ID=73553512

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021007073A MY208153A (en) 2019-05-31 2020-05-29 Solid dispersion and preparation method therefor

Country Status (13)

Country Link
US (1) US20220233449A1 (en)
EP (1) EP3977997A4 (en)
JP (1) JP7603618B2 (en)
KR (1) KR20220016116A (en)
CN (1) CN113825511B (en)
AU (1) AU2020282470A1 (en)
BR (1) BR112021023691A2 (en)
CA (1) CA3141921A1 (en)
MX (1) MX2021014402A (en)
MY (1) MY208153A (en)
TW (1) TW202100527A (en)
WO (1) WO2020239065A1 (en)
ZA (1) ZA202110055B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023182332A1 (en) * 2022-03-22 2023-09-28
KR20240133859A (en) 2023-02-28 2024-09-05 한국표준과학연구원 Screening method of drugs for preventing or treating SARS-CoV-2 using lung oagnoid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0808840A2 (en) * 2007-03-12 2014-09-02 Reddy S Laborartories Ltd Dr IMATINIB MESILATE
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
NZ708272A (en) 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
KR102073797B1 (en) 2014-07-07 2020-02-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Aminopyridazinone compounds as protein kinase inhibitors
WO2016082705A1 (en) * 2014-11-27 2016-06-02 华东理工大学 Insoluble active ingredient particulate, particulate preparation and preparation method therefor
WO2016088074A1 (en) * 2014-12-03 2016-06-09 Dr. Reddy’S Laboratories Limited Process for the preparation of amorphous ibrutinib
CN106924262A (en) * 2015-12-31 2017-07-07 常州方楠医药技术有限公司 A kind of solid dispersions of unformed tropsch imatinib citrate and pharmaceutic adjuvant and preparation method thereof
ES2875384T3 (en) * 2016-01-05 2021-11-10 Jiangsu Hengrui Medicine Co Crystal form of BTK kinase inhibitor and method of its preparation
IN201621020494A (en) * 2016-06-15 2017-12-22
KR102697985B1 (en) 2017-07-04 2024-08-23 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pharmaceutical composition and method for preparing same

Also Published As

Publication number Publication date
BR112021023691A2 (en) 2022-04-12
WO2020239065A1 (en) 2020-12-03
JP2022534610A (en) 2022-08-02
KR20220016116A (en) 2022-02-08
MX2021014402A (en) 2022-02-14
JP7603618B2 (en) 2024-12-20
EP3977997A4 (en) 2022-07-27
US20220233449A1 (en) 2022-07-28
TW202100527A (en) 2021-01-01
AU2020282470A1 (en) 2022-01-27
CN113825511B (en) 2024-10-22
EP3977997A1 (en) 2022-04-06
CN113825511A (en) 2021-12-21
CA3141921A1 (en) 2020-12-03
ZA202110055B (en) 2023-04-26

Similar Documents

Publication Publication Date Title
WO2021062281A3 (en) Multi-targeting effector cells and use thereof
WO2020053365A3 (en) Pesticidally active azole-amide compounds
MX358592B (en) Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents.
MY203853A (en) Crystalline salts of a b-raf kinase inhibitor
DK1303184T3 (en) Preservative and storage agent for biological materials
AU2008266182A8 (en) Metabolites of the janus kinase inhibitor (r)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3- cyclopentylpropanenitrile
ATE289902T1 (en) AZOLE/AMINE OXIDE WOOD PRESERVATIVES AND FUNGICIDES
PH12020550143A1 (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
EP4520398A3 (en) Treatment of prostate cancer
PT3724191T (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
EP4282409A3 (en) Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
WO2023192630A3 (en) Angiotensinogen-modulating compositions and methods of use thereof
HK1248977A2 (en) Method for treating hair, kit, and use of the kit
DK1333812T3 (en) Microgranules based on active substance and process for preparing the same
WO2007018564A3 (en) Enhancement of b cell proliferation by il-15
MX2021014402A (en) DISPERSION OF SOLIDS AND METHOD OF PREPARATION OF THE SAME.
MX2018015388A (en) Compositions for biological systems and methods for preparing and using the same.
WO2022218891A3 (en) Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
MX2020010755A (en) Process for treating hair.
MX2019010271A (en) Applicator system.
SI1186292T1 (en) Dry carotinoid powder with a mulit-core structure
WO2024220930A8 (en) Mapt-modulating compositions and methods of use thereof
EP4335515A3 (en) Crystal forms of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)- 2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1 -yl]acetamide
AU6076500A (en) Hypoestoxides, derivatives and agonists thereof for use as antiparasitic agents
MY199479A (en) Pharmaceutical composition and method for preparing same